Industry
Biotechnology
Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, and in patients with myelofibrosis. It is also developing small molecule product candidate KER-047 that is being developed for the treatment of anemia, and is currently in Phase 1 clinical trial; and KER-012, which is in Phase 1 clinical trial to treat disorders associated with bone loss, such as osteoporosis and osteogenesis imperfecta, and for the treatment of pulmonary arterial hypertension. The company was incorporated in 2015 and is headquartered in Lexington, Massachusetts.
Loading...
Open
N/A
Mkt cap
N/A
Volume
N/A
High
N/A
P/E Ratio
N/A
52-wk high
N/A
Low
N/A
Div yield
N/A
52-wk low
N/A
Portfolio Pulse from Benzinga Newsdesk
June 17, 2024 | 8:08 pm
Portfolio Pulse from Benzinga Newsdesk
June 17, 2024 | 10:05 am
Portfolio Pulse from Benzinga Newsdesk
May 09, 2024 | 11:56 am
Portfolio Pulse from Benzinga Newsdesk
May 08, 2024 | 12:29 pm
Portfolio Pulse from Benzinga Newsdesk
March 27, 2024 | 4:48 pm
Portfolio Pulse from Benzinga Newsdesk
March 14, 2024 | 12:03 pm
Portfolio Pulse from Benzinga Newsdesk
March 13, 2024 | 5:23 pm
Portfolio Pulse from Benzinga Newsdesk
March 01, 2024 | 11:40 am
Portfolio Pulse from Happy Mohamed
February 28, 2024 | 9:33 pm
Portfolio Pulse from Benzinga Newsdesk
January 04, 2024 | 8:37 pm
All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.